{"entity":{"id":"shr-4849","kind":"drug","name":"SHR-4849","aka":["IDE849"],"tldr":"SHR-4849, called IDE849 by IDEAYA Biosciences, is an experimental antibody-drug conjugate aimed at the protein DLL3 in small cell lung cancer and neuroendocrine tumours. Hengrui discovered it and licensed rights outside Greater China to IDEAYA in December 2024.","summary":"SHR-4849 is a DLL3-targeting antibody-drug conjugate with a topoisomerase I inhibitor payload, discovered by Jiangsu Hengrui. IDEAYA Biosciences announced an exclusive licence on 29 December 2024 to develop and sell it outside Greater China, with USD 75 million upfront and up to USD 1.045 billion in total payments, and plans to combine it with its PARG inhibitor IDE161; IDEAYA develops it as IDE849. On 7 September 2025 the two companies presented Hengrui's phase 1 data at the IASLC World Conference on Lung Cancer: 100 patients received doses from 0.8 to 4.2 mg/kg every three weeks, and in second-line small cell lung cancer the confirmed response rate across all expansion doses was 60.0% (21 of 35), with 4 responses still awaiting confirmation; these are early, unconfirmed-in-part results. Registered trials include Hengrui's phase 1 (NCT06443489) and phase 2 combination studies (NCT07028281, NCT07268040), and IDEAYA's phase 1/2 trial in DLL3-expressing tumours (NCT07174583).","status":"phase-2","asOf":"2026-11-03","links":[{"label":"IDEAYA licence announcement, 29 December 2024 (BioSpace copy)","url":"https://www.biospace.com/press-releases/ideaya-biosciences-enters-exclusive-license-with-hengrui-pharma-for-shr-4849-a-novel-phase-1-dll3-topo-i-payload-adc-targeting-sclc-and-net-solid-tumors"},{"label":"IDEAYA and Hengrui phase 1 data at WCLC 2025, 7 September 2025","url":"https://ir.ideayabio.com/2025-09-07-IDEAYA-Biosciences-and-Hengrui-Pharma-Present-Positive-Phase-1-Data-for-IDE849-SHR-4849-,-a-Potential-First-in-Class-DLL3-TOP1-ADC,-in-Small-Cell-Lung-Cancer-at-the-IASLC-2025-World-Conference-on-Lung-Cancer"},{"label":"ClinicalTrials.gov: SHR-4849 phase 1 (NCT06443489)","url":"https://clinicaltrials.gov/study/NCT06443489"}],"tags":["pipeline","deal-asset"],"related":[],"cancers":["sclc"],"sections":[],"technologies":["adc","topoisomerase-inhibitors"],"targets":["dll3"],"drugs":[],"companies":["hengrui","ideaya-biosciences"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07174583","nct07028281","nct07268040"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit (ClinicalTrials.gov v2 + company press releases)","editedOn":"2026-11-03"},"code":"IDE849","modality":"Antibody-drug conjugate (DLL3, topoisomerase I inhibitor payload)","mechanism":"An antibody that recognises DLL3 on small cell lung cancer and neuroendocrine tumour cells carries a topoisomerase I inhibitor, a chemotherapy that breaks DNA, into those cells.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/shr-4849/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"target":[{"id":"dll3","kind":"target","name":"DLL3","route":"/targets/dll3/"}],"company":[{"id":"ideaya-biosciences","kind":"company","name":"IDEAYA Biosciences","route":"/companies/ideaya-biosciences/"},{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}],"trial":[{"id":"nct07174583","kind":"trial","name":"A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer","route":"/trials/nct07174583/"},{"id":"nct07028281","kind":"trial","name":"A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors","route":"/trials/nct07028281/"},{"id":"nct07268040","kind":"trial","name":"A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors","route":"/trials/nct07268040/"}]}}